James Marshall, DO
Internal Medicine · Orange, CTNPI 1871597310
Payments from drug & device makers
Across 54 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$312
- GSK$125
- AstraZeneca$108
- Mylan Specialty L.p.$66
- Genentech USA, Inc.$59
- Inspire Medical Systems, Inc.$56
- plus $363 from 11 others
What the payments were for
- Food & beverage$1,090100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $312 |
| GSK | 6 | $125 |
| AstraZeneca | 6 | $108 |
| Mylan Specialty L.p. | 4 | $66 |
| Genentech USA, Inc. | 4 | $59 |
| Inspire Medical Systems, Inc. | 2 | $56 |
| Lilly USA, LLC | 2 | $52 |
| Novartis | 2 | $44 |
| AbbVie | 2 | $41 |
| Optinose US, Inc. | 2 | $41 |
| Merck | 2 | $33 |
| Boehringer Ingelheim | 2 | $31 |
| Harmony Biosciences LLC | 1 | $29 |
| Philips North America LLC | 2 | $26 |
| Electromed, Inc. | 2 | $25 |
| Novo Nordisk | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
How this compares
$1,090 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 59 | $437 |
| Lisinopril | 54 | $366 |
| Ketoconazole | 11 | $221 |
| Mupirocin | 26 | $219 |
| Amlodipine Besylate | 34 | $219 |
| Levothyroxine Sodium | 12 | $218 |
| Gabapentin | 24 | $209 |
| Atorvastatin Calcium | 36 | $179 |
| Cyclobenzaprine Hcl | 29 | $178 |
| Cephalexin | 16 | $173 |
| Bupropion XlBupropion Hcl | 35 | $143 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $130 |
| Ciprofloxacin Hcl | 29 | $130 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 12 | $123 |
| Mometasone Furoate | 22 | $119 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Orange
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
- Gary BlickNorwalk$717K
- Margaret ChusteckaHamden$652K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.